Skip to main content

The metabolic inhibition model which predicts the intestinal absorbability and Metabolizability of drug: Theory and experiment


The intestinal absorption of analgesic peptides (leucine enkephalin and kyotorphin) and modified peptides in rat were studied. Although these peptides were not absorbed, the absorbability (absorption clearance) of these peptides were increased in the presence of peptidase inhibitors. In order to kinetically analyze these phenomena, we proposed the metabolic inhibition model, which incorporated the metabolic clearance (metabolizability) with the absorption clearance. Metabolic activity was determined with intestinal homogenates. The higher the metabolic clearance was, the lower was the absorption clearance. The relationships between the absorption clearance and the metabolic clearance of the experimental data as well as of the theoretical values were hyperbolic. This model predicted the maximum absorption clearances of cellobiose-coupled leucine enkephalin (0.654 µl/min/cm) and kyotorphin (0.247 µl/min/cm). Details of the experimental methods are described.


  1. 1.

    Mizuma, T., Ohta, K., Koyanagi, A., Awazu, S. 1996. Improvement of intestinal absorption of leucine enkephalin by sugar coupling and peptidase inhibitors. J. Pharm. Sci. 85, 854–857.

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Mizuma, K., Koyanagi, A., Awazu, S. 1997. Intestinal transport and metabolism of analgesic dipeptide, kyotorphin: rate-limiting factor in intestinal absorption of peptide as drug. Biochim. Biophys. Acta 1335, 111–119.

    PubMed  CAS  Google Scholar 

  3. 3.

    Takagi, H., Shiomi, H., Ueda, H., Amano, H. 1979. A novel analgesic dipeptide from bovine brain is a possible Met-enkephalin releaser. Nature 282, 410–412.

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Janicki, P. K., Lipkowski, A. W. 1983. Kyotorphin and D-kyotorphin stimulate Met-enkephalin release from rat striatum in vitro. Neurosi. Lett. 43, 73–77.

    Article  CAS  Google Scholar 

  5. 5.

    Matsubayashi, K., Kojima, C., Kawajiri, S., Ono, K., Takegoshi, T., Ueda, H., Takagi, H. 1984. Hydrolytic deactivation of kyotorphin by the rodent brain homogenates and sera. J Pharmacobio-Dyn. 7, 479–484.

    PubMed  CAS  Google Scholar 

  6. 6.

    Ueda, H., Ming, G., Hazato, T., Katayama, T., Takagi, H. 1985. Degradation of kyotorphin by a purified membrane-bound-aminopeptidase from monkey brain: potentiation of kyotorphin-induced analgesia by a highly effective inhibitor, bestatin. Life Sci. 36, 1865–1871.

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Akasaki, K., Tsuji, H. 1991. An enkephalin-degrading aminopeptidase from rat brain catalyzed the hydrolysis of a neuropeptide, kyotorphin (L-Tyr-L-Arg). Chem. Pharm. Bull. 39, 1883–1885.

    PubMed  CAS  Google Scholar 

  8. 8.

    Orawski, A. T., Simmons, W. H. 1992. Dipeptidase activities in rat brain synaptosomes can be distinguished on the basis of inhibition by bestatin and amastatin: identification of a kyotorphin (Tyr-Arg)-degrading enzyme. Neurochem. Res. 17, 817–820.

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Geary, L. E., Wiley, K. S., Scott, W. L., Cohen, M. L. 1982. Degradation of exogenous enkephalin in the guinea-pig ileum: relative importance of aminopeptidase, enkephalinase and angiotensin converting enzyme activity. J. Pharmacol. Exp. Ther. 221, 104–111.

    PubMed  CAS  Google Scholar 

  10. 10.

    Cohen, M. L., Geary, L. E., Wiley, K. S. 1983. Enkephalin degradation in the guinea-pig ileum: effect of aminopeptidase inhibitors, puromycin and bestatin. J. Pharmacol. Exp. Ther. 224, 379–385.

    PubMed  CAS  Google Scholar 

  11. 11.

    Yamaoka, K., Tanigawara, Y., Nakagawa, T., Uno, T. 1981. A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4, 879–885.

    PubMed  CAS  Google Scholar 

  12. 12.

    Gibaldi, M., Perrier, D. 1982. Pharmacokinetics. Marcel Dekker, Inc. New York. 1–43.

    Google Scholar 

  13. 13.

    Mizuma, T., Sakai, N., Awazu, S. 1994. Na+-Dependent transport of aminopeptidase-resistant sugar-coupled tripeptides in rat intestine. Biochem. Biophys. Res. Commun. 203, 1412–1416.

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Gray, G. R. 1974. The direct coupling of oligosaccharides to protein and derivatized gels. Arch. Biochem. Biophys. 163, 426–428.

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Mizuma, T., Ohta, K., Hayashi, M., Awazu, S. 1992. Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improvement of poorly absorbable drugs. Biochem. Pharmacol. 43, 2037–2039.

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Mizuma, T, Ohta, K. and Awazu, S., unpublished data.

Download references

Author information



Corresponding author

Correspondence to Shoji Awazu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mizuma, T., Awazu, S. The metabolic inhibition model which predicts the intestinal absorbability and Metabolizability of drug: Theory and experiment. Biol Proced Online 1, 32–39 (1998).

Download citation


  • Intestinal Absorption
  • Intestinal Tissue
  • Absorption Experiment
  • Metabolic Clearance
  • Biological Procedure